Natera Inc
NASDAQ:NTRA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
59.21
174
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Natera Inc
Natera Inc
Long-Term Debt
Natera Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Natera Inc
NASDAQ:NTRA
|
Long-Term Debt
$286.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$58.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$56.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$114m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
17%
|
|
Natera Inc
Glance View
In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management. Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.
See Also
What is Natera Inc's Long-Term Debt?
Long-Term Debt
286.5m
USD
Based on the financial report for Sep 30, 2024, Natera Inc's Long-Term Debt amounts to 286.5m USD.
What is Natera Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
31%
Over the last year, the Long-Term Debt growth was 1%. The average annual Long-Term Debt growth rates for Natera Inc have been 1% over the past three years , 31% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet
